Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2018 | Research article

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

Authors: Y. T. Bazargani, M. Ugurlu, A. de Boer, H. G. M. Leufkens, A. K. Mantel-Teeuwisse

Published in: BMC Cardiovascular Disorders | Issue 1/2018

Abstract

Background

The incidence and mortality of cardiovascular diseases (CVDs) in low and middle income countries (LMICs) have been increasing, while access to CVDs medicines is suboptimal. We assessed selection of essential medicines for the prevention and treatment of CVDs on national essential medicines lists (NEMLs) of LMICs and potential determinants for selection.

Methods

Only operational NEMLs were considered eligible for this study. A selection of medicines listed under “cardiovascular medicines” or “blood products and plasma substitutes” in the NEMLs were included if they were present on international guidelines for the prevention and treatment of CVDs (hyperlipidemia, hypertension, platelet inhibition, ischemic stroke, stable ischemic heart disease, acute coronary syndromes, heart failure, atrial fibrillation, peripheral arterial disease and acute limb ischemia). The number and diversity of essential medicines selected for CVDs were studied. Moreover, determinants of selection of essential medicines for CVDs at a national level were explored. Data analysis was done using univariate linear regression and non-parametric tests.

Results

All medicine groups listed by the international guidelines were selected by the majority of the 34 countries studied with the exception of adenosine diphosphate receptor inhibitors which appeared on less than half of the NEMLs studied (41% of countries). The total number of essential medicines for the prevention and treatment of cardiovascular diseases (median 24 (range 16–50)) differed significantly across income levels (median range: 19.5–25, p = 0.014) and across regions (median range: 20–32, p = 0.049). When recommendations of the international guidelines were considered, over 75% of the NEMLs contained essential medicines for the majority of CVDs.

Conclusion

The main medicine classes for the management of CVDs were represented on NEMLs. Consequently, for the majority of CVDs, evidence-based guideline-recommended treatment is possible as far as selection of essential medicines is concerned. Selection will therefore not be the limiting step in access to medicines for cardiovascular diseases.

Available only for authorised users

Mendis S, Puska P, Norrving B. Global atlas on cardiovascular disease Prevention and Control. In: Mendis S, editor. World Health Organization. 1st ed. Geneva: World Health Organization; 2011. p. 2–14.

Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.CrossRefPubMedPubMedCentral

Gaziano TA. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa. Heart. 2008 Feb;94(2):140–4.CrossRefPubMed

Bovet P, Paccaud F. Cardiovascular disease and the changing face of global public Health : a focus on low and middle income countries. Public Health Rev. 2011;33(2):397–415.CrossRef

Mendis S, Alwan A. A prioritized research agenda for prevention and control of noncommunicable diseases. 1st ed. Geneva: World Health Organization; 2011.

Political Declaration of the High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. A/RES/66/2 [Internet]. Geneva: the United Nations. 2012 [cited 2015 Nov 26]. Available from: http://www.who.int/nmh/events/un_ncd_summit2011/political_declaration_en.pdf

Alwan A. Global status report on noncommunicable diseases. 1st ed. Geneva: World Health Organization; 2010. p. 176.

Joshi R, Jan S, Wu Y, MacMahon S. Global inequalities in access to cardiovascular health care. J Am Coll Cardiol. 2008;52(23):1817–25.CrossRefPubMed

Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ. 2011;89(6):412–21.CrossRefPubMedPubMedCentral

10.

Selection of essential medicines [Internet]. Geneva: World Health Organization. 2015 [cited 2015 Sep 23]. Available from: http://www.who.int/selection_medicines/en/

11.

Van de ham R, Bero L, Laing R. The world medicines situation 2011- selection of essential medicines [Internet]. Geneva: World Health Organization. 2011 [cited 2015 Nov 26]. Available from: http://apps.who.int/medicinedocs/documents/s18770en/s18770en.pdf

12.

National Medicines Lists, Formularies and standard treatment guidelines [internet]. Geneva: World Health Organization. 2015 [cited 2015 Nov 26]. Available from: http://www.who.int/selection_medicines/country_lists/en/

13.

Development of Country Profiles and monitoring of the pharmaceutical situation in countries [Internet]. Geneva: World Health Organization. 2015 [cited 2015 Sep 23]. Available from: http://www.who.int/medicines/areas/coordination/coordination_assessment/en/

14.

Country and Lending Groups [Internet]. New York: the World Banknk. 2015 [cited 2015 Nov 10]. Available from: http://data.worldbank.org/about/country-and-lending-groups

15.

WHO regional offices [Internet]. Geneva: World Health Organization. 2015 [cited 2015 Nov 10]. Available from: http://www.who.int/about/regions/en/

16.

Global Burden of Disease [Internet]. Washington, D.C.: Institute for Health Metrics and Evaluation. 2015 [cited 2015 Nov 26]. Available from: http://www.healthdata.org/gbd/data

17.

Camm a J, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012;33(21):2719–47.CrossRefPubMed

18.

Chew DP, Aroney CN, Aylward PE, Kelly A, White HD, Hon F, et al. 2011 addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and new Zealand guidelines for the management of acute coronary syndromes (ACS) 2006. Hear Lung Circ. 2011;20(8):487–502.CrossRef

19.

Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, et al. Management of high blood pressure in blacks: an update of the international society on hypertension in blacks consensus statement. Hypertension. 2010;56(5):780–800.CrossRefPubMed

20.

Fox K, Alonso Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, et al. Guidelines on the management of stable angina pectoris: executive summary - the task force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J. 2006;27(11):1341–81.CrossRefPubMed

21.

Gayet J-L, Paganelli F, Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovasc Dis Elsevier Masson SAS. 2011;104(10):536–44.CrossRef

22.

National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Reducing risk in heart disease: an expert guide to clinical practice for secondary prevention of coronary heart disease. Melbourne: National Heart Foundation of Australia; 2012. p. 20.

23.

Mancini GBJ, Gosselin G, Chow B, Kostuk W, Stone J, Yvorchuk KJ, et al. Canadian cardiovascular society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol Canadian Cardiovascular Society. 2014;30(8):837–49.CrossRef

24.

McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology Developed in collaboration with the Heart. Eur Heart J. 2012;33(14):1787–847.CrossRefPubMed

25.

Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949–3003.CrossRefPubMed

26.

National Heart Foundation of Australia. Guide to management of Hypertension. 2nd ed. Melbourne: National Heart Foundation of Australia; 2010. p. 1–30.

27.

National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. 2011 updated Guidelines for the prevention, detection and management of chronic heart failure in Australia. 2nd ed. Melbourne: National Heart Foundation of Australia; 2011.

28.

Havas S. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Circulation. 2006;106:3143.

29.

National Vascular Disease Prevention Alliance. Guidelines for the management of Absolute cardiovascular disease risk. Melbourne: National Stroke Foundation; 2012. p. 124.

30.

O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, J A d L, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. Jac. 2013;61(4):e78–140.

31.

O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013 ACCF/AHA guideline for the management of st-elevation myocardial infarction: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;61(4):78–140.CrossRef

32.

Parker JD, Parker JO. Stable angina pectoris: the medical management of symptomatic myocardial ischemia. Can J Cardiol Elsevier Inc. 2012;28(2):S70–80.CrossRef

33.

Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice constituted by re. Eur Heart J. 2012;33(13):1635–701.CrossRefPubMed

34.

Reiner Z, Catapano AL, De Backer G, Graham I, Alegria E, Hobbs R. ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769–818.CrossRefPubMed

35.

Roffi M, Valgimigli M, Bax JJ, Borger MA, Gencer B, Germany UL, et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37:267–315.CrossRefPubMed

36.

Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619.CrossRefPubMed

37.

Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clément D, Collet J-P, et al. ESC guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J. 2011;32(22):2851–906.CrossRefPubMed

38.

Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2014;35:2541–619.CrossRefPubMed

39.

Mendis S, Roglic G, Sepulveda C, Shao R. Implementation tools package of essential noncommunicable (PEN) disease interventions for primary health care in low-resource settings. Geneva: World Health Organization; 2013. p. 210.

40.

World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. 1st ed. Geneva: World Health Organization; 2007. p. 67–78.

41.

Mendis S, Chestnov O, Bettcher D. In: Mendis S, editor. Guideline developement and review groups. Prevention and control of noncommunicable diseases: guidelines for primary health care in low-resource settings. 1st ed. Gneneva: World Health Organization; 2012. p. 1–70.

42.

World Health Organization. Prevention of Cardiovascular Disease Prevention of Cardiovascular Disease. 1st ed. Geneva: World Health Organization; 2007. p. 1–30.

43.

Jauch EC, Saver JL, Adams HP, Bruno a, Connors JJ, Demaerschalk BM, et al. Guidelines for the early Management of Patients with Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.CrossRefPubMed

44.

Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the Management of Patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;130:e344–426.CrossRefPubMed

45.

Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and Management of Patients with Stable Ischemic Heart Disease: executive summary. J Am Coll Cardiol Elsevier Inc. 2012;60(24):2564–603.CrossRef

46.

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-society consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45:S5–67.CrossRefPubMed

47.

January MDPF CT, Samuel Wann MDMF L, Alpert MDFF JS, MDFFF HC, Cleveland Jr MDF JC, Cigarroa MDF JE, et al. 2014 AHA/ACC/HRS guideline for the Management of Patients with Atrial Fibrillation. Executive Summary Jac. 2014;64(21):1–57.

48.

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147–239.CrossRefPubMed

49.

Institute of Medicine. In: Fuster V, Kelly BB, editors. Promoting Cardiovascular Health in the Developing World. Washington, D.C: National Academies Press (US); 2010.

50.

Ezzati M, Vander HS. Lopez AD, Danaei G, Rodgers a, Mathers CD, et al. comparative quantification of mortality and burden of disease attributable to selected risk factors. In: Lopez AD, Mathers CD, Ezzati M, editors. Global burden of disease and risk factors. Washington, D.C.: The World Bank; 2006.

51.

Global burden of disease project, GBD compare, Sub-Saharan Africa, both sexes, all ages, 2013, Deaths [Internet]. Washington, D.C.: Institute for Health Metrics and Evaluation. 2015 [cited 2015 Nov 26]. Available from: http://vizhub.healthdata.org/gbd-compare/.

52.

Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan;129(1 Suppl):169S–73S.CrossRefPubMed

53.

Goldman L, Schafer AI. Goldman-Cecil Medicine. 25th ed. New York: Elsevier Health Sciences; 2016. p. 2100.

54.

19th WHO model list of essential medicines [Internet]. Geneva: World Health Organization. 2015 [cited 2015 Nov 26]. Available from: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.

55.

Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, et al. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke. 2014;45(10):3032–9.CrossRefPubMed

56.

Tung CE, Win SS, Lansberg MG. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. Stroke. 2011;42(8):2257–62.CrossRefPubMedPubMedCentral

57.

Pan Y, Chen Q, Zhao X, Liao X, Wang C, Du W, et al. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China. PLoS One. 2014;9(10):e110525.CrossRefPubMedPubMedCentral

58.

Araújo DV, Teich V, Passos RBF, Martins SCO. Analysis of the cost-effectiveness of thrombolysis with alteplase in stroke. Arq Bras Cardiol. 2010;95(1):12–20.CrossRefPubMed

59.

Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JMK. Stroke and thrombolysis in developing countries. Int J Stroke. 2007;2(1):17–26.CrossRefPubMed

60.

Silvain J, Beygui F, Barthélémy O, Pollack C, Cohen M, Zeymer U, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2012;344:e553.CrossRefPubMedPubMedCentral

61.

Junqueira DRG, Perini E, Penholati RRM, Carvalho MG. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev. 2012;9:CD007557.

62.

Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins: implications for prescribing practice and therapeutic interchange. P T. 2010;35(2):95–105.PubMedPubMedCentral

63.

Verhoef TI, Redekop WK, Hasrat F, de Boer A, Maitland-van der Zee AH. Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. Am J Cardiovasc Drugs. 2014;14(6):451–62.CrossRefPubMedPubMedCentral

64.

Harrington AR, Armstrong EP, Nolan PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44(6):1676–81.CrossRefPubMed

65.

Bonet Pla A, Gosalbes Sóler V, Ridao-López M, Navarro Pérez J, Navarro Cubells B, Peiró S. Dabigatran versus acenocumarol for the prevention of stroke in atrial fibrillation: budget impact analysis in one health department in Spain. Rev española salud pública. 2013;87(4):331–42.CrossRef

66.

Bista D, Chalmers L, Bereznicki L, Peterson G. Potential use of NOACs in developing countries: pros and cons. Eur J Clin Pharmacol. 2014;70(7):817–28.CrossRefPubMed

67.

Bergh M, Marais CA, Miller-Jansön H, Salie F, Stander MP. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation. S Afr Med J. 2013;103(4):241–5.CrossRefPubMed

68.

Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, et al. The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ. 2007;85(4):279–88.CrossRefPubMedPubMedCentral

69.

Draft Updated Appendix 3 of the WHO Global NCD Action Plan 2013-2020 [Internet]. Geneva: World Health Organization. 2016 [cited 2017 Nov 23]. Available from: http://www.who.int/ncds/governance/discussion-paper-updating-appendix3-25july2016-EN.pdf.

70.

Duke T, Graham SM, Cherian MN, Ginsburg AS, English M, Howie S, et al. Oxygen is an essential medicine: a call for international action. Int J Tuberc Lung Dis. 2010;14(11):1362–8.PubMed

71.

Linge-Dahl L, Vranken M, Juenger S, North K, Scholten W, Payne S, et al. Identification of challenges to the availability and accessibility of opioids in twelve European countries: conclusions from two ATOME six-country workshops. J Palliat Med. 2015;18(12):1033–9.CrossRefPubMed

72.

Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat. 2011;2011:686797.PubMedPubMedCentral

Title: Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries
Authors: Y. T. Bazargani
M. Ugurlu
A. de Boer
H. G. M. Leufkens
A. K. Mantel-Teeuwisse
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2018
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-018-0858-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Presentation and outcomes of indigenous Australians with peripheral artery disease

Pulmonary vein anatomy variants as a biomarker of atrial fibrillation – CT angiography evaluation

Acute myocardial infarction after blunt chest wall trauma with underlying coronary aneurysm: a case report

The study protocol for PREDICT AF RECURRENCE: a PRospEctive cohort stuDy of surveIllanCe for perioperaTive Atrial Fibrillation RECURRENCE in major non-cardiac surgery for malignancy

The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease

Evaluation of health status and its predictor among university staff in Nigeria

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page